← Leaderboards
Sendurai Ayyavoo Mani
Brown University
$5,773,096
Attributed
$7,084,946
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $864K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,084,946 · 3
By mechanism
R01$7,084,946 · 3
Top collaborators
- Luke Lee Lairson5 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoCellsTumorNeoplasm MetastasisMesenchymalCancer Stem CellResistanceSignal TransductionStem CellsIn VitroLinkMalignant Breast NeoplasmPropertyEpithelialMediatingTraitTranscription FactorMolecularBreast Cancer CellInhibitor/AntagonistCompetenceProgramsRecurrenceCancer Cell
Grant awards (21)
Vimentin Phospho-Malleability is Critical for Maintaining Stemness and Metastatic Properties$381,638
R01 · FY2025 · CA · contact PI
Vimentin Phospho-Malleability is Critical for Maintaining Stemness and Metastatic Properties$375,590
R01 · FY2024 · CA · contact PI
Vimentin Phospho-Malleability is Critical for Maintaining Stemness and Metastatic Properties$397,152
R01 · FY2022 · CA · contact PI
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression$321,099
R01 · FY2022 · CA · contact PI
Vimentin Phospho-Malleability is Critical for Maintaining Stemness and Metastatic Properties$6,225
R01 · FY2022 · CA · contact PI
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression$1,007
R01 · FY2022 · CA · contact PI
Preclinical characterization of EMT/CSC-specific small molecule inhibitors for TNBCs$483,655
R01 · FY2021 · CA · contact PI
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression$328,680
R01 · FY2021 · CA · contact PI
Preclinical characterization of EMT/CSC-specific small molecule inhibitors for TNBCs$51,459
R01 · FY2021 · CA · contact PI
Preclinical characterization of EMT/CSC-specific small molecule inhibitors for TNBCs$535,276
R01 · FY2020 · CA · contact PI
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression$328,680
R01 · FY2020 · CA · contact PI
Preclinical characterization of EMT/CSC-specific small molecule inhibitors for TNBCs$519,217
R01 · FY2019 · CA · contact PI
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression$318,819
R01 · FY2019 · CA · contact PI
Preclinical characterization of EMT/CSC-specific small molecule inhibitors for TNBCs$535,276
R01 · FY2018 · CA · contact PI
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression$328,680
R01 · FY2018 · CA · contact PI
Preclinical characterization of EMT/CSC-specific small molecule inhibitors for TNBCs$550,276
R01 · FY2017 · CA · contact PI
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression$327,462
R01 · FY2015 · CA · contact PI
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression$317,638
R01 · FY2014 · CA · contact PI
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression$309,703
R01 · FY2013 · CA · contact PI
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression$333,707
R01 · FY2012 · CA · contact PI
Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression$333,707
R01 · FY2011 · CA · contact PI